EN DE
Watch UG HEALTHCARE CORPORATIONLTD for free: we tell you when fair value or trend changes.
Data-driven stock valuation

UG HEALTHCARE CORPORATIONLTD (8K7) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of UG HEALTHCARE CORPORATIONLTD stock S$0.08, price S$0.07, upside +6.4%, quality 65 out of 100. Rating: fairly valued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SG · ISIN SGXE48766716

UH UG HEALTHCARE CORPORATIONLTD logo Thin data Nov 16, 2026

UG HEALTHCARE CORPORATIONLTD

8K7 · SG

Solid company, but the stock is already about fairly priced and falling price: meets 1 of 3 rules.

Get notified free when this changes
Quality 65/100 
Low debt 
Generates free cash flow 
Fair value 0.0788 SGD · Fairly valued 
Thin margins · 1.4% net margin (TTM) 
Mixed vs. peers (6/12) 
Falling price (downtrend) 
Weak Growth (revenue 5y −14.9 %/yr in SGD) 
Narrow moat 25/100 · thin data
Thin data 
Watch UG HEALTHCARE CORPORATIONLTD for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

0.5391 SGD 0.0700 SGD Fair Value 0.0788 SGD Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range 0.0700 SGD – 0.5391 SGD · fair‑value band 0.0713 SGD – 0.0938 SGD · the 0.0740 SGD price screens below the 0.0788 SGD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow UG HEALTHCARE CORPORATIONLTD in your weekly email

Every Wednesday you see whether UG HEALTHCARE CORPORATIONLTD is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

UG Healthcare Corporation Limited, an investment holding company, manufactures and sells disposable gloves. It operates through Latex Examination Gloves, Nitrile Examination Gloves, and Other Ancillary Products segments.

Show moreShow less

The company distributes ancillary products, including surgical, vinyl, and cleanroom disposable gloves and reusable gloves, as well as face masks, and other medical disposables.

It serves customers under the Unigloves brand name in Europe, North America, South America, Africa, Asia, and internationally. UG Healthcare Corporation Limited was founded in 1989 and is based in Singapore.

Stock analysis

UG HEALTHCARE CORPORATIONLTD (8K7) currently trades at 0.0740 SGD, while our model-based Fair Value estimate is 0.0788 SGD, so the stock looks roughly fairly valued today (gap 6.0%).

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of 0.3350 SGD per share, and 19 of the 24 models we run sit above the 0.0740 SGD price.

Bear case: the Earnings-Based group reads lowest at 0.0600 SGD, and 5 of the 24 models stay below the price. Data coverage for this calculation is low.

Scenario range: 0.0713 SGD (bear) to 0.0938 SGD (bull), the price of 0.0740 SGD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 65/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

UG HEALTHCARE CORPORATIONLTD reported revenue of 151M SGD in FY2026 versus 233M SGD in FY2022, a compound −10.3%/yr. Reported net income was 2.1M SGD in FY2026, compounding −51.1%/yr from FY2022.

Key figures

Market cap 46.2M SGD (≈ $35.8M) Micro · P/S ratio 0.31 · Net margin 1.4% · Return on equity 1.6% · Return on assets (EBIT) 1.2% (5-year average) · Operating margin 7.5% · Revenue (TTM) 151M SGD · Revenue growth (YoY) +6.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 25 out of 100 (low confidence).

What moves the price

The share trades about 29% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at 6%, 8K7 screens cheaper than that median.

Fair Value models

Bear 0.0713 SGD Fair Value 0.0788 SGD Bull 0.0938 SGD
Price 0.0740 SGD · Upside +6.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF 0.2800 SGD 0.4900 SGD 0.8600 SGD 74
EPV 0.0700 SGD 0.0800 SGD 0.0900 SGD 73
Growth DCF 0.2800 SGD 0.4700 SGD 0.8000 SGD 73
All 24 models by family
DCF Models
FCF DCF 0.2800 SGD 0.4900 SGD 0.8600 SGD 74
Owner Earnings 0.1800 SGD 0.3200 SGD 0.5600 SGD 70
5Y Revenue Exit 0.1400 SGD 0.2000 SGD 0.2800 SGD 69
5Y EBITDA Exit 0.1900 SGD 0.3100 SGD 0.4500 SGD 71
5Y P/E Exit 0.1300 SGD 0.1800 SGD 0.2400 SGD 68
10Y Revenue Exit 0.1800 SGD 0.2600 SGD 0.3600 SGD 64
10Y EBITDA Exit 0.2200 SGD 0.3300 SGD 0.5000 SGD 65
10Y P/E Exit 0.1800 SGD 0.2400 SGD 0.3300 SGD 62
Earnings-Based
Graham-Dodd 0.0200 SGD 0.1100 SGD 0.1500 SGD 62
Lynch FV 0.0300 SGD 0.0400 SGD 0.0500 SGD 60
PEG = 1.0 0.0300 SGD 0.0400 SGD 0.0500 SGD 56
EPV 0.0700 SGD 0.0800 SGD 0.0900 SGD 73
Multiples
P/E Multiple 0.0600 SGD 0.0700 SGD 0.0900 SGD 63
P/S Multiple 0.0400 SGD 0.0600 SGD 0.0700 SGD 57
P/B Multiple 0.1000 SGD 0.1300 SGD 0.1600 SGD 55
EV/EBIT 0.0700 SGD 0.1000 SGD 0.1300 SGD 64
EV/EBITDA 0.1400 SGD 0.1900 SGD 0.2400 SGD 67
EV/Revenue 0.0500 SGD 0.0800 SGD 0.1000 SGD 52
Asset-Based
NCAV (Graham) 0.1000 SGD 0.1400 SGD 0.1800 SGD 54
Growth DCF
Growth DCF 0.2800 SGD 0.4700 SGD 0.8000 SGD 73
Rev-Margin DCF 0.1400 SGD 0.2000 SGD 0.2900 SGD 69
Economic Profit
Residual Income 0.1700 SGD 0.1800 SGD 0.1900 SGD 68
ROIC Compounder 0.0700 SGD 0.0800 SGD 0.0900 SGD 69
Growth Earnings
Growth-Adj P/E 0.0500 SGD 0.0700 SGD 0.0900 SGD 66

Open the full fair value analysis →

Quality Score breakdown

Overall quality 65/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 27
How much profit the company makes from its sales and capital
Quality Growth 71
Are margins and returns getting better?
Cashflow 69
Do the profits arrive as real cash?
Financial strength 64
Debt, balance sheet and risk of trouble
Investment 98
Does it invest with discipline instead of growing at any price?
Low Volatility 58
How calm the share price moves, does not count
Price momentum 27
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 9
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+4.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−14.9%
Start year 2021 (pandemic). Over 10 years: +9.9% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.8%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−43.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−43.6%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−43.6% vs −2.3%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.46% → 4%
Pace: the 5-year rate starts in 2021 (pandemic)

Growth Forecast

Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−15.4%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Singapore: IMF forecast 2.0% a year to 2030, 1.7% from 2016 to 2025) that is about −17.0% a year for the price.

Watch 8K7, get fair value alerts →

Compare UG HEALTHCARE CORPORATIONLTD with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 199 stocks

Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 65 · Above median
Fair Value upside +6.5% · Above median
Profitability
Return on equity (12 months) 1.6% · Below median
Return on assets 1.1% · Below median
Net margin (12 months) 1.8% · Below median
Operating margin (12 months) 7.5% · Below median
Growth and dividend
Revenue growth (quarter YoY) 6.6% · Below median
Balance sheet
Debt / equity 0.11× · Above median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 0.27× · Cheapest 25%
P/S (12 months) 0.39× · Cheapest 25%
Price / free cash flow (fiscal year) 4.1× · Cheapest 25%
EV/EBITDA 4.6× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)42 · sector 17
FUTURE (revenue growth)33 · sector 40
PAST (return on equity)6 · sector 26
HEALTH (low debt)95 · sector 96
DIVIDEND (yield)0 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $89.08 $131.27 +47% vs 8K7
EssilorLuxottica Société anonyme EL €184.50 €196.22 +6% vs 8K7
Intuitive Surgical, Inc ISRG $443.59 $353.90 −20% vs 8K7
Medline Inc MDLN $39.47 $28.59 −28% vs 8K7
Alcon Inc ALC CHF 62.14 CHF 35.08 −44% vs 8K7
Becton, Dickinson and Company BDX $218.03 $97.80 −55% vs 8K7
Straumann Holding STMN CHF 108.75 CHF 45.50 −58% vs 8K7
West Pharmaceutical Services, Inc WST $416.42 $139.22 −67% vs 8K7
Sartorius Stedim Biotech S.A DIM €225.20 €54.82 −76% vs 8K7
Sartorius Aktiengesellschaft SRT €226.50 €46.44 −80% vs 8K7

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

UG HEALTHCARE CORPORATIONLTD: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "UG HEALTHCARE CORPORATIONLTD Fair Value". https://www.fairvalue-calculator.com/stock/8K7

Frequently asked questions

Is UG HEALTHCARE CORPORATIONLTD (8K7) overvalued or undervalued?
As of Nov 16, 2026, our model estimates a fair value of 0.0788 SGD versus a price of 0.0740 SGD, about +6% upside (fairly valued).
What is the fair value of 8K7?
Our model-based fair value for UG HEALTHCARE CORPORATIONLTD is 0.0788 SGD (as of Nov 16, 2026), built from audited fundamentals. The current price: 0.0740 SGD.
What is the quality score of 8K7?
UG HEALTHCARE CORPORATIONLTD has a Quality Score of 65/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for UG HEALTHCARE CORPORATIONLTD (8K7)?
Our model-based price target is the fair value of 0.0788 SGD (as of Nov 16, 2026) from 24 valuation models. Cautious scenario 0.0713 SGD, optimistic scenario 0.0938 SGD. It is a calculation from audited fundamentals, not an analyst target.
What is the UG HEALTHCARE CORPORATIONLTD stock forecast for 2026?
Our models put fair value at 0.0788 SGD, about +6% upside versus a price of 0.0740 SGD (fairly valued). Cautious scenario 0.0713 SGD, optimistic scenario 0.0938 SGD. The calculation is refreshed regularly with new filings.
What is the revenue of UG HEALTHCARE CORPORATIONLTD (8K7)?
UG HEALTHCARE CORPORATIONLTD reported trailing-twelve-month revenue of about 151M SGD (latest available figure, as of Nov 16, 2026).
What growth is priced into UG HEALTHCARE CORPORATIONLTD (8K7)?
Today's price is already fair in a discounted-cash-flow model if free cash flow at UG HEALTHCARE CORPORATIONLTD shrinks by 15.4 % per year for five years (discount rate 9.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue fell 14.9 % per year. As of Nov 16, 2026.
What discount rate (WACC) does the fair value of 8K7 use?
Our models discount UG HEALTHCARE CORPORATIONLTD at 9.1 %: a base by market capitalisation (nano), damped by beta 0.83, country premium for Singapore. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For UG HEALTHCARE CORPORATIONLTD that is -15.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.1 %) and the same formula as our fair value.
How much growth has UG HEALTHCARE CORPORATIONLTD (8K7) delivered so far?
Over the past 5 years revenue at UG HEALTHCARE CORPORATIONLTD shrank 14.9 % a year. The price currently implies free-cash-flow growth of -15.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of UG HEALTHCARE CORPORATIONLTD (8K7) growing?
The median revenue growth in the sector is +7.3 % a year. That is the yardstick for the growth priced into UG HEALTHCARE CORPORATIONLTD (-15.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of UG HEALTHCARE CORPORATIONLTD (8K7)?
The free-cash-flow yield on the price is 30.65 %: that much free cash flow UG HEALTHCARE CORPORATIONLTD produces per unit of market value. When it exceeds the discount rate of our models (9.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of UG HEALTHCARE CORPORATIONLTD (8K7)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For UG HEALTHCARE CORPORATIONLTD it is 0.0788 SGD per share (as of Nov 16, 2026), against a price of 0.0740 SGD. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is UG HEALTHCARE CORPORATIONLTD stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 8K7 trades below its calculated fair value: price 0.0740 SGD, fair value 0.0788 SGD, a gap of about +6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 8K7?
No. The price is what the market pays today (0.0740 SGD); the fair value is what the company's own numbers justify (0.0788 SGD). For UG HEALTHCARE CORPORATIONLTD the two are 0.0048 SGD per share apart. That gap is exactly why we show both numbers side by side.
How much is UG HEALTHCARE CORPORATIONLTD worth?
The market values UG HEALTHCARE CORPORATIONLTD at about 46.2M SGD (market capitalisation, as of Nov 16, 2026). Per share that is 0.0740 SGD; our models calculate a fair value of 0.0788 SGD per share.
What do the bullish and bearish scenarios say about 8K7?
Our models span a range for UG HEALTHCARE CORPORATIONLTD: cautious scenario 0.0713 SGD, base 0.0788 SGD, optimistic 0.0938 SGD per share (as of Nov 16, 2026, price 0.0740 SGD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of UG HEALTHCARE CORPORATIONLTD (8K7)?
Balance-sheet figures for UG HEALTHCARE CORPORATIONLTD (as of Nov 16, 2026): return on equity 1.6%, debt of 0.11 per unit of equity. They feed the Quality Score of 65/100, which measures business quality independently of the share price.
How far is 8K7 from its 52-week high?
UG HEALTHCARE CORPORATIONLTD trades at 0.0740 SGD, about 29% below its 52-week high of 0.1040 SGD and 6% above the low of 0.0700 SGD (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of 0.0788 SGD is for.
Which stocks are comparable to UG HEALTHCARE CORPORATIONLTD?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is UG HEALTHCARE CORPORATIONLTD stock attractive at the current price?
The data as of Nov 16, 2026: price 0.0740 SGD, calculated fair value 0.0788 SGD (+6%), Quality Score 65/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 8K7 calculated?
We run UG HEALTHCARE CORPORATIONLTD through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 0.0788 SGD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. UG HEALTHCARE CORPORATIONLTD currently trades 6% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of UG HEALTHCARE CORPORATIONLTD (8K7)?
The closing price on Nov 16, 2026 was 0.0740 SGD. Our model-based fair value is 0.0788 SGD, about +6% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with UG HEALTHCARE CORPORATIONLTD right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of UG HEALTHCARE CORPORATIONLTD

How large is the market capitalisation of UG HEALTHCARE CORPORATIONLTD (8K7)?
The market capitalisation of UG HEALTHCARE CORPORATIONLTD is 46.2M SGD (≈ $35.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of UG HEALTHCARE CORPORATIONLTD (8K7)?
The price-to-sales ratio of UG HEALTHCARE CORPORATIONLTD is 0.31 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of UG HEALTHCARE CORPORATIONLTD (8K7)?
The net margin of UG HEALTHCARE CORPORATIONLTD is 1.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of UG HEALTHCARE CORPORATIONLTD (8K7)?
The return on equity (ROE) of UG HEALTHCARE CORPORATIONLTD is 1.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of UG HEALTHCARE CORPORATIONLTD (8K7)?
On an EBIT basis the return on assets of UG HEALTHCARE CORPORATIONLTD is 1.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of UG HEALTHCARE CORPORATIONLTD (8K7)?
The operating margin of UG HEALTHCARE CORPORATIONLTD is 7.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at UG HEALTHCARE CORPORATIONLTD (8K7)?
Revenue at UG HEALTHCARE CORPORATIONLTD is growing 6.6% versus a year earlier (3y avg +14.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at UG HEALTHCARE CORPORATIONLTD (8K7)?
Earnings per share at UG HEALTHCARE CORPORATIONLTD are down 83.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does UG HEALTHCARE CORPORATIONLTD (8K7) carry?
The net debt of UG HEALTHCARE CORPORATIONLTD is 11.8M SGD (fiscal year 2026, ≈ 0.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch UG HEALTHCARE CORPORATIONLTD in the live analysis

One click puts UG HEALTHCARE CORPORATIONLTD on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.